Best Ophthalmology podcasts — Eye and vision research (Updated June 2017; image)
Related podcasts: Science Medicine Health and Well-Being Tech Isrs Neuro-ophthalmology Oculoplastics Uveitis Lasek Lasik Sclera Macula Amd Aao Neuro Retina Glaucoma Cornea Cataract Neurology  
public [subscription 1120]
show episodes
 
M
Medscape Ophthalmology Podcast
Monthly
 
Latest medical news and features from Medscape Ophthalmology
 
A
As Seen From Here
Monthly+
 
the Ophthalmology podcast
 
O
OIS Podcast
Weekly
 
Welcome to the Ophthalmology Innovation Podcast where you get candid conversations with the leaders & drivers of ophthalmic innovation.
 
Loading …
show series
 
After capturing lighting in a bottle with Oculeve, Ali Behbahani, MD, partner of New Enterprise Associates, recalls the experience with the Dry Eye start-up and lays out his plans for investing in future ophthalmology start-ups.
 
Max G. Ostermeier, MBA, co-founder and general manager of Implandata Ophthalmic Products GmbH, charts a course for the company after securing CE mark for its EYEMATE eye pressure measurement system for continuous measurement of IOL in patients with glaucoma.
 
Physicians from all over the country tell Medscape about their experiences with the ACA. What's your take?
 
Guest: Priya Narang, MS Narang Eye Care & Laser Centre Ahmedabad, India
 
Mynosys Cellular Devices CEO and president John Hendrick lays out his company’s plan to roll out Zepto in the US. The firm has reported strong demand in OUS markets, and Hendrick anticipates it will upend the capsulotomy market.
 
Eric Donnenfeld, MD, founding partner of OCLI, shares how his practice is incorporating new diagnostics and treatments. “I spend less time diagnosing the disease and it enables me to spend more time talking to the patients about therapies,” Dr. Donnenfeld says. He also praises Shire and Allergan for their effective marketing.…
 
Guests: Arsham Sheybani, MD Assistant Professor Ophthalmology and Visual Sciences Washington University School of Medicine St Louis, MO Devesh Varma, MD Assistant Professor Department of Ophthalmology & Vision Sciences University of Toronto School of Medicine Toronto, ON, Canada
 
In this interview, Tom Mitro, COO of Aerie Pharmaceuticals, says new hires brought on to prepare for likely commercial sale of Rhopressa bring new life and energy into a company hitting its stride. He also provides to OIS@ASCRS an update on the firm’s glaucoma pipeline.
 
Ludwin Monz, PhD, President and CEO of Carl Zeiss Meditec explains why the ophthalmology leader brought in new senior leadership. He also reviews the company’s recent product approvals and gives an assessment of the “amazing possibilities” within diagnostics.
 
Now that Shire’s Xiidra claims a 20% market share, find out how it’s impacting the practice. Alice Epitropoulos, MD, of Ophthalmic Surgeons & Consultants of Ohio, sat down with OIS-TV to explain how Shire, TrueTear, and other advances are impacting her Dry Eye patients.
 
Guest: Greg Moloney, MD Mosman, Australia
 
LensGen CEO Ram Rao discusses his company’s $21 million Series A and the increased interest in presbyopia.
 
Guests: Ehud Assia, MD Professor of Ophthalmology Tel-Aviv University Medical School Tel-Aviv, Israel Jeffrey Whitman, MD   Dallas, TX
 
Emmett Cunningham, MD, Gil Kliman, MD, and Bill Link, PhD, co-chairs of OIS, talk about device funding, myopia, and the Masters of the Industry following a successful OIS@ASCRS.
 
Gil Kliman, managing director at InterWest Partners, reviews his role at the upcoming OIS@ASCRS, including an overview of anterior segment innovation and a discussion on lower myopia.
 
Longtime eye bank executive David Korroch, chief executive officer, Lions Medical Eye Bank, explains how eye banks have worked hard to meet – and even exceed – the demand for donated tissue. Korroch is the winner of this year’s Leonard Heise Award.
 
A
As Seen From Here
 
Guest: Jodhbir Mehta, MD Associate Professor, Head of Cornea External Disease, Senior Consultant in Refractive Surgery Singapore National Eye Centre Singapore
 
Mark S. Blumenkranz, MD, H. J. Smead Professor of Ophthalmology, Emeritus, delivers his State of Innovation address. You can guess what his assessment is, but we’ll give you a hint. It involves cool lasers.
 
Guests: Garry Condon, M.D. Pittsburgh, PA Robert J. Cionni, M.D. Salt Lake City, UT
 
OIS Co-Chair William J. Link, PhD walks us through OIS@ASCRS’ May 4 agenda, which takes place in LA. Link also explains why he Andy Corley and Richard Lindstrom, MD, formed Flying L Partners. Hear about the firm’s most recent investment.
 
From his clinic in South Dakota, Vance Thompson has served as an investigator in over 60 clinical trials. Thompson taps this experience to shed some light on new innovations being brought forth by Zeiss, Avedro, Allergan, and RxSight. He also offers a few insights on new advances coming down the pike.…
 
In 2015, three patients who had a stem cell mixture injected in their eyes were severely injured. To try to prevent this from happening again, their treating physicians reached out to the FDA and clinical societies, and ultimately they wrote a paper for the New England Journal of Medicine to warn others about the dangers of these so-called trea ...…
 
Guest: Guy J. Ben Simon, MD Professor of Ophthalmology Sackler Faculty of Medicine Tel Aviv University Tel Aviv, Israel
 
Post-concussion, oculomotor and binocular visual issues are more likely to disrupt kids' schooling, says Dr Christina Master.
 
Newly appointed President and CEO Nancy Lurker explains why she took over as CEO and President at pSivida and gives details on the company’s early clinical testing results in the recurrence of uveitis. Lurker hits upon filing for regulatory approval filings, building a sale team and operating a drug company at a time of political uncertainty.…
 
Dr Jeffrey Weber assesses the benefit of immunotherapies in two rare subtypes of melanoma and finds that rates of survival and duration of response trail well behind those associated with cutaneous melanoma.
 
Last month, Minnesota Eye Consultants announced it was working with private equity investor Waud Capital to create an entity that could build a national eye care provider. In part two of our interview with MEC founder Richard Lindstrom, MD, we discuss the impact similar consolidations could have on the sector.…
 
Guests: Jodhbir Mehta, MD Associate Professor, Head of Cornea External Disease, Senior Consultant in Refractive Surgery Singapore National Eye Centre Singapore Alvin L. Young, MD Chief of Service, Department of Ophthalmology & Visual Sciences Prince of Wales and Alice Ho Miu Ling Nethersole Hospitals The Chinese University of Hong Kong Hong Kong…
 
Consolidation is coming to ophthalmology. Last month, Minnesota Eye Consultants agreed to partner with a private equity group to expand beyond the Twin Cities. In the first of a two-part podcast, founder Richard Lindstrom, MD, explains why the deal was done.
 
Cedric Francois, co-founder, CEO, and president of Apellis delivers an update on his start-up’s promising complement therapies. He also shares why he joined other Biotech CEOs and VCs in speaking against the proposed immigration restrictions.
 
Guest: Dr Laura Downie, PhD Senior Lecturer, NHMRC Translating Research Into Practice (TRIP) Fellow University of Melbourne Melbourne , Australia
 
On February 28, the National Eye Institute will host a webinar to introduce its 3D Retina Organoid Challenge. Its objective is simple: use $1 million in prize money to encourage researchers from multiple disciplines to create a critical tool for retinal research. The NEI’s Jessica Mazerik and Steve Becker share the details, which can also be fo ...…
 
Ophthalmology CEO turned VC Abbie Celniker, now a partner at Third Rock Ventures, discusses her role at the firm and reveals how it will invest its new $616 million fund.
 
Guest: Dr Laura Downie, PhD Senior Lecturer, NHMRC Translating Research Into Practice (TRIP) Fellow University of Melbourne Melbourne , Australia
 
With Novartis’ acquisition of Encore Vision setting the standard, CEO Jim McCollum and CSO Jerry Horn, MD, tell the tale of Presbyopia Therapies, a small start-up that is working to develop “lifestyle” eye drops that can help presbyopes read without assistance.
 
Frederic Guerard, head of Novartis’ ophthalmology franchise, explains why the global giant was the last strategic standing in the competitive bidding to acquire the promising, but very early stage, start-up. Novartis will resume testing of the new presbyopia-correcting ophthalmic solution, now dubbed UNR-844.…
 
The threat of Medicare clamping down on drug prices has never loomed larger. Sanford Bernstein’s Ronny Gal and Liav Abraham of Citi gauge the risk and explain how ophthalmology drug companies might be impacted.
 
Guests: Gerod Sutton, M.D. Professor of Ophthalmology Sydney Medical School Foundation Sydney, Australia Vishal Jhanji, M.D. Associate Professor of Ophthalmology Director, Cornea and Refractive Surgery Service Chinese University of Hong Kong Eye Hong Kong
 
Christian Roesky, PhD, joins the OIS Podcast to explain why he became the new CEO and managing director of Novaliq GmbH, a specialty pharma company with a novel drug delivery platform technology that can make drugs more effective in treating ophthalmic disorders. He also delves into the company’s positive Phase II evaluating CyclASol in 207 pat ...…
 
EyeGate CEO Stephen From reports positive results of Phase Ia/IIb trials of EGP-437, regulatory progress for its Ocular bandage gel, and potential fundraising plans.
 
Guests: Joseph B. Ciolino, MD Henry Freeman Allen Cornea Scholar Schepens Eye Research Institute Harvard Medical School Massachusetts Eye and Ear Infirmary Boston, MA Daniel S. Kohane MD, PhD. Professor of Anesthesia Harvard Medical School Boston, MA
 
Guests: Joseph B. Ciolino, MD Henry Freeman Allen Cornea Scholar Schepens Eye Research Institute Harvard Medical School Massachusetts Eye and Ear Infirmary Boston, MA Daniel S. Kohane MD, PhD. Professor of Anesthesia Harvard Medical School Boston, MA
 
KOLs, CEOs, and analysts say Ophthotech’s disappointing Fovista trials alter the landscape for companies developing new treatments for wet AMD. And all agree, the biggest losers in all of this are patients suffering from the disease.
 
Three-year-old TearSolutions hopes to pen a strong sequel to SARCode’s successful tale of a start-up developing the next new treatment for Dry Eye Disease. Tom Gadek, co-founder of SARCode, developer of lifitegrast (now Shire’s potential blockbuster Xiidra), takes over the company as it begins courting partners and investors.…
 
The majority of infants born with congenital CMV infection are asymptomatic and thus missed with current screening strategies. What are the pros and cons of universal screening?
 
Guests: Luca Gualdi, M.D. DOMA (Dignostica Oculistica e Microchirurgia Ambulatoriale) Rome, Italy Michael Korchak, M.D. Weill Cornell Medical College New York, NY
 
Carl Zeiss Meditec continues to add top talent. Andrew Chang, who managed US sales at B&L, joins the growing group bringing him together with Unit Head Jim Mazzo.
 
This has been a busy year for Thomas Frinzi, senior vice president of Abbott’s vision business. He took the helm of Abbott Medical Optics in January. In July, the FDA approved the company’s promising new Tecnis Symfony IOL. Then Johnson & Johnson agreed to pay $4 billion to acquire the vision device company in September. What’s next?…
 
The election of Donald Trump had an immediate impact on our OIS Index. OIS writers and editors dig deeper, discussing what the long-term impact could be on drug prices, regulation and the ophthalmology’s bottom line?
 
Guest: Young Hee Yoon, MD,PhD, Professor, Department of Ophthalmology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
 
Speed
Series preference
1x
1x
Volume
100%
/

Google login Twitter login Classic login